FindTrial
Sign In

Antibody Titers of Two Dose Intradermal Pre-exposure Rabies Prophylaxis Regimen in Children with No Known Immunodeficiency Versus Children Exposed to Immunosuppressant Therapy

Immunogenicity Of Accelerated Two Dose Intradermal Pre-Exposure Rabies Prophylaxis Regimen In Children With No Known Immunodeficiency Versus Children Exposed To Immunosuppressant Therapy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046777
Enrollment
40
Registered
2022-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M089- Juvenile arthritis, unspecified

Interventions

Intervention1: Administration of cell culture anti-rabies vaccine as part of two dose intradermal pre-exposure prophylaxis regimen: 0.1 ml of Cell culture anti-rabies vaccine will be administered via

Sponsors

Department Of Pediatrics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children and adolescents aged 5-18 years

Exclusion criteria

Exclusion criteria: 1. History of receipt of any rabies vaccine. 2. Previous severe allergic reaction to any of the vaccine components.

Design outcomes

Primary

MeasureTime frame
If mean antibody titers (IU/ml) after two dose pre-exposure rabies prophylaxis are comparable in children with no known immunodeficiency versus children exposed to immunosuppressant therapyTimepoint: At day 0, 28 and 90—

Secondary

MeasureTime frame
Adverse effect profile after two dose intradermal pre-exposure rabies prophylaxisTimepoint: At day 0 and 7—

Countries

India

Contacts

Public ContactDr Charu Singh

Department Of Pediatrics, Maulana Azad Medical College, New Delhi

doctoranuragagarwal@gmail.com9810409625

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026